This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Better Diagnosis Of Acute Heart Failure Using Pronota's Novel Biomarker

GHENT, Belgium, April 18, 2013 /PRNewswire/ --

Two independent validation studies demonstrate that Pronota's biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, provides clinicians with unique additional information allowing better treatment of this challenging group of patients.

Current diagnosis for acute heart failure is limited

Current clinical practice for triaging patients with shortness of breath includes the measurement of specific peptides (B-type natriuretic peptides: BNP or NT-proBNP). Despite the widespread use of these biomarkers, there is still much room for improvement. "Natriuretic peptides have become standard tools to support making the correct diagnosis in patients with shortness of breath.  However, clinicians clearly recognize the limitations of natriuretic peptides. The potential value of another biomarker to improve the diagnostic accuracy of BNP or NT-proBNP is considerable," commented Prof. J. Januzzi (Massachusetts General Hospital, Harvard Medical School).

Pronota's novel heart failure marker for accurate diagnosis

Pronota identified the biomarker CD146 from an unbiased proteomics effort. Its performance has now been confirmed in two independent studies totaling over 500 patients. Prof. A. Mebazaa (INSERM, Paris, France), principal investigator for the validation studies, commented: "It is exciting to see that novel biomarkers with underlying biological processes completely different from currently used biomarkers can still be discovered and validated. This not only provides more insight into the underlying disease mechanism, it also gives the physician tools to improve the management and care of heart failure patients. Pronota's approach in this respect is unique and has proven to deliver on numerous occasions."

Launch forecast: 2014

"Data from early verification and marker characterization studies were already highly exciting, but the recent independent validation studies exceeded our expectations and would not have been possible without the support of our network of key opinion leaders in the field," commented Katleen Verleysen, CEO of Pronota NV. "We anticipate launching this product in 2014, so that clinicians may get access to the tools they need to improve the treatment and care of their patients."

http://www.pronota.com

SOURCE Pronota

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs